301 related articles for article (PubMed ID: 30919077)
21. Cataract development in patients treated with proton beam therapy for uveal melanoma.
Seibel I; Cordini D; Hager A; Riechardt AI; Rehak M; Böker A; Böhmer D; Heufelder J; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1625-1630. PubMed ID: 27116211
[TBL] [Abstract][Full Text] [Related]
22. Iris nevi and melanomas: a clinical follow-up study.
van Klink F; de Keizer RJ; Jager MJ; Kakebeeke-Kemme HM
Doc Ophthalmol; 1992; 82(1-2):49-55. PubMed ID: 1305027
[TBL] [Abstract][Full Text] [Related]
23. Proton beam therapy for iris melanoma: a review of 15 cases.
Rundle P; Singh AD; Rennie I
Eye (Lond); 2007 Jan; 21(1):79-82. PubMed ID: 16410818
[TBL] [Abstract][Full Text] [Related]
24. Iris melanocytic tumours in New Zealand/Aotearoa: presentation, management and outcome in a high UV exposure environment.
Rapata MEJ; Zhang J; Cunningham WJ; Hadden PW; Patel DV; McGhee CNJ
Eye (Lond); 2023 Mar; 37(4):692-699. PubMed ID: 35338357
[TBL] [Abstract][Full Text] [Related]
25. Proton therapy for uveal melanoma in 43 juvenile patients: long-term results.
Petrovic A; Bergin C; Schalenbourg A; Goitein G; Zografos L
Ophthalmology; 2014 Apr; 121(4):898-904. PubMed ID: 24405742
[TBL] [Abstract][Full Text] [Related]
26. Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and Outcome.
Seibel I; Cordini D; Rehak M; Hager A; Riechardt AI; Böker A; Heufelder J; Weber A; Gollrad J; Besserer A; Joussen AM
Am J Ophthalmol; 2015 Oct; 160(4):628-36. PubMed ID: 26133249
[TBL] [Abstract][Full Text] [Related]
27. Trabeculectomy in patients with uveal melanoma after proton beam therapy.
Riechardt AI; Cordini D; Rehak M; Hager A; Seibel I; Böker A; Gundlach E; Heufelder J; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1379-85. PubMed ID: 26960442
[TBL] [Abstract][Full Text] [Related]
28. Proton Therapy for 166 Patients with Iris Melanoma: Side Effects and Oncologic Outcomes.
Gollrad J; Böker A; Vitzthum S; Besserer A; Heufelder J; Gauger U; Böhmer D; Budach V; Zeitz O; Joussen AM
Ophthalmol Retina; 2023 Mar; 7(3):266-274. PubMed ID: 36087876
[TBL] [Abstract][Full Text] [Related]
29. Mortality after diagnosis of small melanocytic lesions of the choroid.
Lane AM; Egan KM; Kim IK; Gragoudas ES
Arch Ophthalmol; 2010 Aug; 128(8):996-1000. PubMed ID: 20696999
[TBL] [Abstract][Full Text] [Related]
30. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM
Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837
[TBL] [Abstract][Full Text] [Related]
31. [Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy].
Gambrelle J; Kodjikian L; Rouberol F; Donate D; Duquesne N; Jean-Louis B; Chauvel P; Gérard JP; Romestaing P; Grange JD
J Fr Ophtalmol; 2004 Jan; 27(1):40-7. PubMed ID: 14968076
[TBL] [Abstract][Full Text] [Related]
32. [Uveal and iridociliary melanomas in young patients : A retrospective analysis of 57 cases].
Heyer LJ; Metz C; Flühs D; Heyer CM; Bornfeld N
Ophthalmologe; 2016 Dec; 113(12):1046-1050. PubMed ID: 27286673
[TBL] [Abstract][Full Text] [Related]
33. Limbal Stem Cell Preservation During Proton Beam Irradiation for Diffuse Iris Melanoma.
Singh AD; Dupps WJ; Biscotti CV; Suh JH; Lathrop KL; Nairn JP; Shih H
Cornea; 2017 Jan; 36(1):119-122. PubMed ID: 27755196
[TBL] [Abstract][Full Text] [Related]
34. No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
Sabazade S; Herrspiegel C; Gill V; Stålhammar G
BMC Cancer; 2021 Nov; 21(1):1270. PubMed ID: 34819035
[TBL] [Abstract][Full Text] [Related]
35. Proton Beam Irradiation: A Safe Procedure in Postequatorial Extraocular Extension From Uveal Melanoma.
Seibel I; Riechardt AI; Erb-Eigner K; Böker A; Cordini D; Heufelder J; Joussen AM
Am J Ophthalmol; 2018 Jul; 191():49-53. PubMed ID: 29655645
[TBL] [Abstract][Full Text] [Related]
36. [Diffuse malignant melanoma of the uvea. A clinico-histopathologic study of 39 patients].
Braun UC; Rummelt VC; Naumann GO
Klin Monbl Augenheilkd; 1998 Dec; 213(6):331-40. PubMed ID: 10048010
[TBL] [Abstract][Full Text] [Related]
37. Proton beam therapy and iris neovascularisation in uveal melanoma.
Boyd SR; Gittos A; Richter M; Hungerford JL; Errington RD; Cree IA
Eye (Lond); 2006 Jul; 20(7):832-6. PubMed ID: 16167079
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates].
Desjardins L; Lumbroso L; Levy C; Mazal A; Delacroix S; Rosenwald JC; Dendale R; Plancher C; Asselain B
J Fr Ophtalmol; 2003 Mar; 26(3):269-76. PubMed ID: 12746603
[TBL] [Abstract][Full Text] [Related]
39. [Clinical analysis of tumors of the iris and ciliary body].
Liu GQ; Wu ZY; Feng GG; Yang HS; Yan JH; Zheng HL
Zhonghua Yan Ke Za Zhi; 2003 Feb; 39(2):77-80. PubMed ID: 12783684
[TBL] [Abstract][Full Text] [Related]
40. Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.
Riechardt AI; Pilger D; Cordini D; Seibel I; Gundlach E; Hager A; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2263-2269. PubMed ID: 28721444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
